Clinical trials
Diffuse Glioma clinical trials
Below are recruiting diffuse glioma clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05956821RecruitingPhase 1/Phase 2
Study drug for young people with recurring brain glioma
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
Miami, FloridaAges 1–21 - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT07608003Recruiting
MRI AI model study for midline brain tumors
This study uses artificial intelligence to analyze MRI scans of midline brain tumors (gliomas) to help predict how the disease may progress and improve treatment planning. Researchers are collecting data from multiple hospitals to teach an AI system to better understand these tumors.
Changsha, HunanAges Any age - NCT05717699RecruitingPhase 1
Trial of a virus treatment for DIPG in children
This Phase 1 trial tests a lab-made cancer virus (Ad-TD-nsIL12) in children with DIPG whose tumor keeps growing after standard treatment. It mainly focuses on safety and how the treatment works, and it may help shrink or control the tumor by stimulating the immune system.
Beijing, Beijing MunicipalityAges 1–18 - NCT05717712RecruitingPhase 1
Study virus treatment for newly diagnosed DIPG in children
This Phase 1 trial tests a type of cancer-fighting virus given directly into the tumor for children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The goal is to see if it can be delivered safely and to learn how the body responds to it.
Beijing, Beijing MunicipalityAges 1–18 - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
San Francisco, CaliforniaAges 2–21 - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+ - NCT04655404RecruitingEarly Phase 1
Larotrectinib for children with newly diagnosed glioma with NTRK fusion
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
Aurora, ColoradoAges Up to 21 years - NCT07240662Recruiting
Vorasidenib for IDH-mutant Grade 2 glioma
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
HeidelbergAges 18 years+ - NCT06468176Recruiting
Remote program for memory and thinking after brain tumor
This study tests a remote program to help with memory and thinking problems caused by a grade 2 or 3 brain tumor. It is for people who have had surgery and are at least 6 months past any radiation or chemotherapy.
Montpellier, HéraultAges 18 years+ - NCT05096481RecruitingPhase 2
Vaccine for brain tumors in children and young adults
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
Aurora, ColoradoAges 3–39 - NCT06203496Recruiting
Monitoring brain tumors with blood tests
This trial studies whether a blood test can track the progress of a type of brain tumor called a grade 4 diffuse glioma. It may offer a less invasive way to monitor these tumors after surgery.
CaenAges 18 years+ - NCT04099797RecruitingPhase 1
CAR T therapy for certain GD2 brain tumors
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
Houston, TexasAges 1–25 - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65 - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Phoenix, ArizonaAges Any age - NCT07076498RecruitingPhase 1
Gene therapy for children and adults with diffuse midline glioma
This trial tests a modified herpes virus (M032) given directly into the brain tumor after standard radiation. The goal is to see if this virus can slow or stop the growth of diffuse midline glioma, a type of brain cancer.
Houston, TexasAges 3 years+ - NCT06492486RecruitingPhase 2
Brain tumor radiation study using AI planning
This trial tests a new way to plan radiation therapy for brain tumors (gliomas) using artificial intelligence. It aims to make treatment more precise and personalized for people with either aggressive (GBM) or slower-growing (IDH-mutant) gliomas.
Mumbai, MaharatshtraAges 18–70 - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT07865195Recruiting
Study of brain tumors in Réunion island residents
This study gathers information about people diagnosed with a type of brain tumor called diffuse glioma in Réunion island. It aims to better understand the disease, its impact, and the care provided, which may help improve future treatments and support.
Saint-PierreAges Any age - NCT06831461Recruiting
Proton vs photon radiation for brain tumors
This study compares two types of radiation therapy for adults with primary brain tumors that have a good outlook (expected survival longer than 5 years). You will receive either standard photon radiation or the more targeted proton radiation, to see if one works better or causes fewer side effects.
MumbaiAges 18–70 - NCT05622409Recruiting
Tissue and genetic data registry for diffuse glioma in adults
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
Kaohsiung CityAges 20 years+ - NCT06305910RecruitingPhase 1
Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Minneapolis, MinnesotaAges 2–25 - NCT05259605Recruiting
Study uses brain tumor tissue and scans to track treatment outcomes
This is an observational study that collects and compares information from patients with primary brain tumors and their treatment results. It uses stored tumor tissue and brain scans to better understand outcomes using updated tumor classification methods.
InnsbruckAges 18 years+ - NCT06357377RecruitingPhase 1
NEO100 for children with high-grade brain tumors
This trial tests a new drug called NEO100 for children with certain types of brain tumors. It is given through a needle into the tumor or nearby fluid, and the study looks at safety and the right dose.
Orange, CaliforniaAges 5–18
Hear when a new Diffuse Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse glioma?
- Yes. Clin2 currently lists 61 recruiting diffuse glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.